Vor Biopharma receives Nasdaq deficiency notice for bid price below $1.00

Vor Biopharma Inc.

Nasdaq notified Vor Biopharma on Aug 29, 2024 that its common stock bid price has been below $1.00 for 30 consecutive business days.
Company has until Feb 25, 2025 to regain compliance by closing at or above $1.00 for at least 10 consecutive business days.
If not compliant by Feb 2025, Vor may transfer to Nasdaq Capital Market for an additional 180-day grace period, subject to other listing requirements.
Delisting risk exists if compliance not regained or transfer not completed; company monitoring options including potential reverse stock split.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.